Good morning :)
Place Order
Add to Watchlist

Gujarat Themis Biosyn Ltd

GUJTHEM

Gujarat Themis Biosyn Ltd

GUJTHEM
Health CarePharmaceuticals
SmallcapWith a market cap of ₹3,674 cr, stock is ranked 886
High RiskStock is 3.96x as volatile as Nifty
337.200.06% (+0.20)
337.200.06% (+0.20)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹3,674 cr, stock is ranked 886
High RiskStock is 3.96x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹3,674 cr, stock is ranked 886
High RiskStock is 3.96x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
67.2018.250.20%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
52.566.720.47%

Forecast & Ratings

Detailed Forecast 
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

The company makes bulk drugs. It's R&D division focuses on developing fermentation cultures. The Company's products include Rifamycin-S, which is an intermediate for Rifampicin for the treatment of tuberculosis (TB), and Lovastatin.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 32.13%, vs industry avg of 9.03%

Increasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 0.02% to 0.05%

Higher than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 55.96%, vs industry avg of 15.28%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue32.7936.0538.9743.2686.8293.83118.90154.98174.20162.87
Raw Materialssubtract0.321.492.151.3015.4415.7521.7529.7325.6785.28
Power & Fuel Costsubtract17.1517.9919.3320.2022.8616.5721.7326.4126.53
Employee Costsubtract4.284.424.465.176.437.117.087.7510.21
Selling & Administrative Expensessubtract0.940.851.101.391.641.862.316.668.51
Operating & Other expensessubtract3.904.905.525.626.918.943.944.2020.18
Depreciation/Amortizationsubtract1.201.121.151.221.361.732.232.583.543.93
Interest & Other Itemssubtract0.380.410.420.160.920.980.830.180.230.27
Taxes & Other Itemssubtract0.000.500.971.797.5910.7115.4119.5020.1818.71
EPS0.420.400.360.592.172.774.005.329.0525.09
DPS0.000.000.000.000.220.001.470.723.330.63
Payout ratio0.000.000.000.000.100.000.370.140.370.03

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2022

Annual report

PDF

Investor Presentation

Nov 15PDF
Nov 15PDF
Sep 13PDF
Sep 13PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Gujarat Themis Biosyn Ltd62.1218.250.20%
Sun Pharmaceutical Industries Ltd47.576.790.71%
Cipla Ltd30.804.740.83%
Torrent Pharmaceuticals Ltd71.4717.270.80%

Price Comparison

Compare GUJTHEM with any stock or ETF
Compare GUJTHEM with any stock or ETF
GUJTHEM
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding70.86%1.17%0.01%1.44%26.51%

Sep 2023

Dec 2023

Mar 2024

Jun 2024

Shareholding History

MarJunSepDec '23MarJun0.01%0.01%0.01%0.87%1.05%1.44%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 4 Mutual Funds holding Gujarat Themis Biosyn Ltd




Funds (Top 4)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
quant Manufacturing Fund - Growth Option - Direct Plan

Growth
0.9856%3.36%1.16%10/45 (+5)
Quant Value Fund - Direct Plan Growth Growth

Growth
0.2553%0.45%0.24%22/54 (-2)
Bandhan BSE Healthcare Index Fund Direct Plan-Growth

Growth
0.0004%0.09%0.09%77/102 (-1)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateJul 15, 2024

Final
Final | Div/Share: ₹0.25

Dividend/Share

0.25

Ex DateEx Date

Jul 15, 2024

Cash Dividend

Ex DateEx DateFeb 22, 2024

Interim
Interim | Div/Share: ₹0.75

Dividend/Share

0.75

Ex DateEx Date

Feb 22, 2024

Cash Dividend

Ex DateEx DateSep 1, 2023

Final
Final | Div/Share: ₹1.00

Dividend/Share

1.00

Ex DateEx Date

Sep 1, 2023

Cash Dividend

Ex DateEx DateDec 1, 2022

Interim
Interim | Div/Share: ₹4.40

Dividend/Share

4.40

Ex DateEx Date

Dec 1, 2022

Cash Dividend

Ex DateEx DateAug 29, 2022

Final
Final | Div/Share: ₹4.00

Dividend/Share

4.00

Ex DateEx Date

Aug 29, 2022

News & Opinions
Spotlight
Gujarat Themis' Q1 PAT falls over 25% YoY to Rs 13 crore

This decline was primarily driven by a 21.7% YoY drop in net sales to Rs 38.83 crore. Total operating expenses also decreased by 22.2% to Rs 20.28 crore in the June'24 quarter. Consequently, PBIDT decreased by 22.4% YoY to Rs 19.07 crore in Q1 FY25, with a margin of 49.11% (down from 49.57% in Q1 FY24). Further, the company's depreciation charges increased by 53.3% YoY to Rs 1.15 crore during the period under review. As a result, profit before tax fell by 25% to Rs 17.86 crore in Q1 FY25 compared to Rs 23.81 crore in the corresponding quarter of the previous year. Gujarat Themis Biosyn is engaged in the manufacturing of APIs, namely, Rifamycin S and Rifamycin O. The scrip had declined 3.91% to end at Rs 483.75 on the BSE on Friday. In the last one year, the stock of Gujarat Themis Biosyn has surged 207.26% while the benchmark Sensex had risen 21.92% in the same period. Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Board of Gujarat Themis Biosyn appoints director

The Board of Gujarat Themis Biosyn has approved the appointment of K. G. Ananthakrishnan (DIN: 00019325) as an Additional Independent Director of the Company w.e.f. 26 July 2024. Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Gujarat Themis Biosyn fixes record date for bonus issue

Gujarat Themis Biosyn has fixed 09 August 2024 as record date for issuance of bonus shares. Powered by Capital Market - Live

2 months agoCapital Market - Live
Earnings
Gujarat Themis Biosyn standalone net profit declines 25.28% in the June 2024 quarter

Net profit of Gujarat Themis Biosyn declined 25.28% to Rs 13.24 crore in the quarter ended June 2024 as against Rs 17.72 crore during the previous quarter ended June 2023. Sales declined 21.70% to Rs 38.83 crore in the quarter ended June 2024 as against Rs 49.59 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales38.8349.59 -22 OPM %47.8047.43 - PBDT19.0124.56 -23 PBT17.8623.81 -25 NP13.2417.72 -25 Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Gujarat Themis Biosyn schedules board meeting

Gujarat Themis Biosyn will hold a meeting of the Board of Directors of the Company on 26 July 2024.Powered by Capital Market - Live

2 months agoCapital Market - Live